Clinical Trial

RenovoRx sets a key update call, juggling early RenovoCath device sales with its pivotal Phase III pancreatic cancer trial, a beacon for patients.

IntraBio's landmark FDA submission for levacetylleucine offers the first glimmer of an approved therapy for the devastating rare disease Ataxia-Telangiectasia.

The National Bleeding Disorders Foundation taps celebrity power for a live event, aiming to spotlight underdiagnosed conditions and transform advocacy.

Biotech firm Humacyte raises $20M to accelerate sales of its FDA-approved Symvess® and fund crucial trials for new hemodialysis applications.

A novel drug designed to eliminate stubborn cancer proteins enters human trials, offering a new strategy for ALK+ lung cancer patients facing resistance.

With pivotal trials advancing, key FDA alignment, and a strong cash position, Taysha Gene Therapies charts a clear path toward a potential breakthrough.

Annovis Bio's new trial for buntanetap uses an AI-powered Apple Watch app to track symptoms, aiming for more precise data in the race for a cure.

A new biotech spins out with a novel drug class aiming to provide healthier, more durable weight loss and combat cancer-related wasting syndrome.

A new $7 million deal will use a digital marketplace to deliver 16 million doses of a life-saving antibiotic to children in Burkina Faso. But can it work?

Biotech firm ProMIS Neurosciences reveals novel vaccine data for ALS and Parkinson's, using a platform that selectively targets only toxic proteins.

With a massive $68.7M seed round and novel T-cell engager tech, Shanghai's Excalipoint is pioneering a new model for rapid drug development.

A novel drug mimicking exercise aims to solve a major problem with today's weight-loss meds: muscle loss. Atrogi's ATR-258 has entered a key human trial.

SAB Biotherapeutics' public offering fuels late-stage trials for its promising T1D drug, SAB-142, aiming to change the treatment landscape.

A new injectable dye entering Phase 3 trials promises to make lung cancer cells glow, helping surgeons remove tumors more completely and prevent recurrence.

After regaining Nasdaq compliance, Incannex Healthcare is leveraging its $75M war chest to advance novel treatments for sleep apnea and anxiety.

Galectin Therapeutics adds legendary neurosurgeon Dr. Henry Brem to its board, a strategic move to leverage his drug development expertise for its lead liver drug.

A new exoskeleton, validated by scientific studies, shows a dramatic reduction in muscle strain and discomfort for surgeons, dentists, and industrial workers.

The biotech reports promising clinical data for its lead alpha-therapy program and secures funding into late 2027, navigating a high-cost, high-reward path.

San Diego biotech elevates key execs as it advances its inflammation pipeline, backed by Sanofi and Lilly, into a competitive and high-stakes market.

A new needle-delivered electrode could make advanced nerve stimulation less invasive, opening up a massive market beyond spinal cord surgery.